Septic shock, a life-threatening infection, is among the most common reasons for admission to ICUs in Manitoba and is a leading cause of death. Septic shock leads to uncontrolled inflammation and coagulation abnormalities. Apart from antibiotics and supportive care, there are few treatments available. Cancer patients are at higher risk of infections and septic shock due to immunosuppression from the underlying disease and chemotherapy.
New book from Institute researcher, Dignity in Care: The Human Side of Medicine helps shape the future of patient care
Senior Scientist at CancerCare Manitoba Research Institute, Dr. Harvey Max Chochinov has published a new book, Dignity in Care: The Human Side of Medicine, providing insight into how the disposition and attitude of healthcare providers indelibly shape patient experience.
New trial looks at reducing bleeding risk in cancer patients while also developing novel research methods
A new Investigator-Initiated Clinical Trial (IICT) led by Primary Investigator, Dr. Brett Houston, called the MYELO-CAN TXA trial, aims to see whether Tranexamic Acid (TXA) can help prevent bleeding in patients with certain blood cancers such as acute leukemia and myelodysplastic syndrome.